<DOC>
	<DOCNO>NCT02978183</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ST266 ophthalmic drop compare placebo treatment sign symptom allergic conjunctivitis .</brief_summary>
	<brief_title>Evaluation Effectiveness ST266 Ophthalmic Drops Compared Placebo Treat Allergic Conjunctivitis</brief_title>
	<detailed_description>The study multi-center , double-masked , randomize , placebo-controlled , modified conjunctival allergen challenge ( CAC ) model . The primary endpoint ocular itch conjunctival redness evaluate subject 's final visit . Subjects meet inclusion criterion randomize one two treatment group ( 1:1 ) . Randomization stratify average post-CAC itching score baseline . Subjects evaluate baseline Days 6 , 7 8 .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>least 18 year age either gender race ; provide write informed consent sign HIPAA form ; willing able follow instruction attend study visit ; positive history ocular allergy positive skin test reaction seasonal AND perennial allergen confirm allergic skin test ; able willing avoid disallow medication appropriate washout period study ; able willing discontinue wear contact lens least 72 hour prior study trial period ; ( female capable become pregnant ) agree urine pregnancy test perform screening ( must negative ) study exit ; must lactate ; must agree use medically acceptable form birth control throughout study duration least 14 day prior instillation investigational product ) . Women consider capable become pregnant include female experience menarche experience menopause ( define amenorrhea great 12 consecutive month ) undergo successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) ; calculate visual acuity 0.7 logMAR good eye measure use ETDRS chart ; positive postCAC reaction ; positive postCAC reaction two first three time point ; able selfadminister eye drop satisfactorily caregiver home routinely available purpose . know contraindication sensitivity use investigational product component ; ocular condition , opinion investigator , could affect subject 's safety trial parameter ( include limit narrow angle glaucoma , clinically significant blepharitis , follicular conjunctivitis , iritis , pterygium ) ; ocular surgical intervention within 3 month prior initiate study study and/or history refractive surgery within past 6 month ; know history retinal detachment , diabetic retinopathy , active retinal disease ; presence active ocular infection ( bacterial , viral fungal ) positive history ocular herpetic infection visit ; use disallow medication period indicate prior study ; significant illness ( e.g . autoimmune disease require therapy , severe cardiovascular disease [ include arrhythmias ] ) investigator feel could expect interfere subject 's health study parameter and/or put subject unnecessary risk ( include limit : poorly control hypertension poorly control diabetes , history status asthmaticus , organ transplant , know history persistent moderate severe asthma , know history moderate severe allergic asthmatic reaction study allergen ) ; manifest sign symptom clinically active allergic conjunctivitis either eye screening visit ; plan surgery ( ocular systemic ) trial period within 30 day ; use investigational drug medical device within 30 day study concurrently enrol another investigational product trial ; female currently pregnant , plan pregnancy , lactate . cancer history cancer within last 5 year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>